Faculty News
In an op-ed, Professor Aswath Damodaran cautions against Pfizer's acquisition of Allergan
—
Excerpt from Forbes -- "The bottom line is that this looks like a bad deal for the wrong company, at the wrong time and at the wrong price -- the wrong company because Allergan’s accounting statements are a mine field due to acquisition accounting, the wrong time because we may actually be on the verge of a major change in US corporate tax code and at the wrong price because of the premium on an already large market capitalization."
Read more
Read more